First-Line Eftilagimod Alpha Plus Pembrolizumab/Chemo Yields Responses in Advanced Nonsquamous NSCLC

ICI-Chemo Combo Delivers More Benefit Than Harm, Even for High-Risk NSCLC Patients, Study Finds

Immune checkpoint inhibitors, such as Opdivo (nivolumab) and Keytruda (pembrolizumab), have been a huge advance in the treatment of non-small cell lung cancer. But it is open question whether they should be combined with traditional chemotherapy.

Strategies to Minimize Toxicities, and the Pharmacist’s Role in Educating and Supporting Patients With NSCLC

A panelist discusses how to minimize EGFR tyrosine kinase inhibitor (TKI) adverse effects through preventive measures such as maintaining good skin regimens with moisturizers and SPF 30+ sunscreen, prescribing topical steroids and antibiotics for skin rash, and managing diarrhea with hydration, diet modifications, and loperamide.

First-Line Eftilagimod Alpha Plus Pembrolizumab/Chemo Yields Responses in Advanced Nonsquamous NSCLC

First-line eftilagimod alpha plus pembrolizumab and chemotherapy produced responses in advanced nonsquamous non–small cell lung cancer.

Efti Plus Keytruda With Chemo Shows High Response in NSCLC Subset

Efti plus Keytruda and chemo achieved a 61% response rate in first-line advanced non-squamous non–small cell lung cancer, outperforming historical data.